ADAMs and ADAMTSs in cancer

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• ADAMs (a disintegrin and metalloproteinase domain) and ADAMTSs (ADAMs with thrombospondin motifs) are multi-domain protein families.
• These proteins possess metalloproteinase and disintegrin-like domains, with ADAMs typically being transmembrane proteins and ADAMTSs being secreted.
• Dysregulated expression of ADAMs and ADAMTSs is frequently observed in human cancers, often correlating with cancer progression.

Purpose of the Study:

• To review recent developments in the role of ADAM and ADAMTS proteins in human cancer.
• To elucidate how these proteins modulate the tumor microenvironment and influence cancer progression.
• To explore the dual roles of ADAMs and ADAMTSs as both promoters and inhibitors of cancer.

Main Methods:

• Literature review of recent research on ADAM and ADAMTS proteins in cancer.
• Analysis of the proteolytic activities of ADAMs (ectodomain shedding) and ADAMTSs (ECM proteoglycan degradation).
• Examination of the mechanisms by which these proteins influence cancer cell proliferation, migration, angiogenesis, and dissemination.

Main Results:

• ADAMs function as ectodomain sheddases, releasing bioactive molecules that impact cancer.
• ADAMTSs degrade extracellular matrix proteoglycans, remodeling the tumor microenvironment.
• Both protein families can promote cancer progression (e.g., via proliferation, migration, angiogenesis) or inhibit it (e.g., via integrin interaction, antiangiogenic activity).

Conclusions:

• ADAM and ADAMTS proteins play complex and often opposing roles in human cancer.
• Their involvement spans modulation of the tumor microenvironment, cell signaling, and metastasis.
• Targeting ADAMs and ADAMTSs presents potential therapeutic strategies for cancer treatment.